AI is transforming biotech by accelerating drug discovery, diagnostics, and research. Emerging AI-biotech companies still need flexible wet lab space, advanced equipment, and experimental validation to bring discoveries to market.

Labshares and Byte51 help biotech startups navigate fundraising with investor data, competitive insights, market trends, and access to a funding intelligence platform powered by more than $650 billion in science and VC data.

Explore what the biotech rebound means for emerging companies, from renewed investment and pharma partnerships to disciplined growth, flexible lab infrastructure, and capital-efficient operations.